Nathalie Mason
Clinical Researcher
Key Impact
Notable for experimental and early-phase clinical studies characterising the subjective, physiological and potential therapeutic effects of classical psychedelics and novel tryptamines in humans.
Background & Research
Dr. Nathalie Mason is a clinical researcher specialising in human experimental psychopharmacology and early-phase clinical trials of psychedelic compounds. Her work spans controlled laboratory studies in healthy volunteers and phase 1/2 clinical investigations in patients, with a particular focus on classical serotonergic psychedelics (psilocybin, LSD) and rapidly acting tryptamines (notably inhaled 5‑MeO‑DMT). She has been involved in placebo-controlled and dose-ranging studies that probe acute subjective effects, pain perception, immune changes, and safety/tolerability profiles, and in translational trials assessing a vapourised 5‑MeO‑DMT formulation (GH001) for treatment‑resistant depression.